A Phase 3, Multi-center, Placebo-controlled, Randomized, Double-blind 26-week Study to Assess the Safety and Efficacy of CaPre in Patients With Severe Hypertriglyceridemia.

Trial Profile

A Phase 3, Multi-center, Placebo-controlled, Randomized, Double-blind 26-week Study to Assess the Safety and Efficacy of CaPre in Patients With Severe Hypertriglyceridemia.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2018

At a glance

  • Drugs Omega-3 phospholipid (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms TRILOGY 1
  • Sponsors Acasti Pharma
  • Most Recent Events

    • 27 Jun 2018 According to an Acasti Pharma media release, 463 patients enrolled and 41 patients randomized at 110 clinical sites till date. And topline data from study is expexted by the end of 2019
    • 11 Jun 2018 According to an Acasti Pharma media release, an update on the progress of this trial was presented at the XVIIIth International Symposium on Atherosclerosis (ISA2018).
    • 14 Mar 2018 According to an Acasti Pharma media release, the company expects to obtain the topline data from TRILOGY program (TRILOGY 1 and TRILOGY 2) by the end of 2019, which along with data from CaPres two Phase 1 and two Phase 2 trials will support the submission of a new drug application to the FDA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top